Elaprase is a prescription medication used in the treatment of Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II). This rare, inherited genetic disorder is characterized by a deficiency of the enzyme iduronate-2-sulfatase, which is necessary for the breakdown of certain complex molecules in the body. Without adequate levels of this enzyme, these molecules accumulate in various tissues and organs, leading to a range of symptoms including skeletal abnormalities, breathing difficulties, heart issues, and cognitive impairment. Elaprase, a form of enzyme replacement therapy (ERT), works by providing patients with a synthetic version of the enzyme they lack, helping to manage the symptoms of the disease and improve quality of life. It is typically administered through intravenous infusion and is intended for long-term treatment.